tdf

In this episode, Princy N. Kumar, MD, FIDSA, MACP, discusses key considerations for selecting ART in treatment-naive persons with HIV. Her discussion includes a review of the following studies on ART and weight gain:

• ADVANCE: men vs women receiving DTG + FTC/TAF, DTG + FTC/TDF, and EFV + FTC/TDF
• Comparison of ART regimens (eg, INSTI-, NNRTI- and PI-based regimens) in a pooled analysis of 8 phase III randomized controlled trials
• GEMINI-1 and GEMINI-2: DTG + 3TC vs DTG + FTC/TDF

Presenter:
Princy N. Kumar, MD, FIDSA, MACP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.

Link to full program:
https://bit.ly/3VIsDTg

Follow along with the slides:
https://bit.ly/3PYy1zn

In this episode, Princy N. Kumar, MD, FIDSA, MACP, discusses key considerations for selecting ART in treatment-naive persons with HIV. Her discussion includes:

• DHHS Treatment Guideline recommendations
• Choosing among first-line recommended integrase inhibitors
• Recommended regimens for rapid ART start
• Select key studies in treatment-naïve adults:
  • AMBER study of virologic response with DRV/COBI/FTC/TAF vs DRV/COBI + TFC/TDF
  • DRIVE-AHEAD and DRIVE-FORWARD efficacy study results, including resistance analyses of DOR + 2 NRTIs vs EFV or (DRV + RTV) + 2 NRTIs
  • Safety and efficacy results from GEMINI-1 and GEMINI comparing DTG + 3TC vs DTG + FTC/TDF
• The current/possible role of boosted PIs and NNRTIs
• Selection considerations between TDF and TAF

Presenter:
Princy N. Kumar, MD, FIDSA, MACP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.

Link to full program:
https://bit.ly/3VIsDTg

Follow along with the slides:
https://bit.ly/3PYy1zn

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from AASLD 2022, including:

• Hepatitis B
• Prevention of HBV vertical transmission when HBIg is unavailable
• Therapeutic vaccination for HBV cure
• Antiviral therapy to prevent HCC in patients with CHB in the indeterminate phase
• Hepatitis delta
• HDV prevalence in ethnically diverse, urban, safety-net populations
• Bulevirtide ± pegIFN-α2a for chronic HDV in the French cATU study
• Bulevirtide monotherapy for patients with HDV and compensated cirrhosis in the HEP4Di study
• HDV functional cure with lonafarnib-based therapy
• Hepatitis C
• Integrated community HCV service for PWUD: the ITTREAT study
• Helios-3 study of treatment of people with HCV by specialists or nonspecialists
• Risk of HCC after SVR in patients with HCV

Presenter:

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I 
JW Goethe University Hospital 
Frankfurt, Germany

Follow along with the downloadable slideset at: 
https://bit.ly/3FxIOwZ

Link to full program: 
https://bit.ly/3Y1tD6f

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, focuses on transgender women. His discussion includes: 

• Barriers to PrEP uptake in transgender women
• High PrEP adherence among transgender women and transfeminine individuals in a real-world healthcare setting in New York City

Presenter: 

Timothy J. Wilkin, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York

Link to full program:
http://bit.ly/3UFUl2b

Follow along with the slides at:
https://bit.ly/3EcaYg0

This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses PrEP uptake for cisgender women. His discussion includes: 

• Prevalence of PrEP use in cisgender women in the United States
• Barriers to PrEP uptake in cisgender women
• Implementation of PrEP within family planning clinics in Atlanta
• PrEP in pregnancy and breastfeeding

Presenter: 

Timothy J. Wilkin, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York

Link to full program: 
http://bit.ly/3UFUl2b

Follow along with the slides at:
http://bit.ly/3TDOPM8

In this episode, Paul E. Sax, MD, discusses the latest recommendations and options for HIV pre-exposure prophylaxis (PrEP), including:

• CDC PrEP guideline 2021 updates for oral PrEP
• The ANRS IPERGAY study: on-demand oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) PrEP in men who have sex with men who are at high risk for HIV infection
• A review of the HPTN 083 and 084 studies: efficacy and safety of long-acting (LA) injectable cabotegravir (CAB) vs daily oral FTC/TDF for PrEP
• 1-year follow-up after unblinding for HPTN 083 and 084
• LA CAB for PrEP: monitoring and safety
• Stopping LA CAB for PrEP

Presenter: 

Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Link to full program:
https://bit.ly/3VIsDTg

Follow along with the slides at:
https://bit.ly/3Gh9AKG

How do we define “older” in our older patients living with hepatitis B virus (HBV)? What monitoring and treatment options should be considered for these older patients with chronic HBV infection?

Listen as Nancy Reau, MD, discusses strategies and considerations for monitoring and treating older adults with HBV, illustrated with a patient case.

Presenter:

Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology  
Associate Director, Solid Organ Transplantation  
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Link to full program:
https://bit.ly/3T1UImw

In this episode, Chloe Orkin, MBChB, FRCP, MD​, discusses strategies for successful antiretroviral therapy (ART) initiation. Her overview includes:

• Recommendations for rapid ART
• First-line ART regimens for treatment-naive people with HIV
• IMEA 055 FAST study
• STAT study
• DIAMOND study
• Antiretroviral resistance mutations
• Patient perspectives on the importance of rapid ART initiation

Presenter:

Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London​
Consultant Physician​
Lead for HIV Research
Barts Health NHS Trust​
The Royal London Hospital​
London, United Kingdom​

Panelists:

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​
Director
Desmond Tutu HIV Centre​
Past President
International AIDS Society​
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa​

Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​
Chief and Director
VHS Infectious Diseases Medical Centre​
Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site​
Voluntary Health Services​
Chennai, India

Babafemi Taiwo, MBBS​
Gene Stollerman Professor of Medicine​
Chief, Division of Infectious Diseases​
Northwestern University
Feinberg School of Medicine​
Chicago, Illinois

Content based on an online CME program supported by an independent educational grant from Gilead Sciences.

Follow along with the slides: 
https://bit.ly/3dSNoum

Link to full program:
https://bit.ly/3AE2AV1

In this podcast, Latesha Elopre, MD, MSPH discusses options for pre-exposure prophylaxis (PrEP). Listen as she explains best practices for the nonpharmacologic prevention of HIV, as well as oral and injectable pharmacologic PrEP options.

Presenters:

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, Alabama

Moderator

Jason Farley, PhD, MPH, ANP-BC, FAAN, AACRN
Endowed Professor of Nursing Leadership and Innovation
Johns Hopkins University School of Nursing
Director, Center for Infectious Disease and Nursing Innovation
Adult Nurse Practitioner, Infectious Diseases
Johns Hopkins Medicine
Baltimore, Maryland

In this podcast, Latesha Elopre, MD, MSPH discusses inequities in pre-exposure prophylaxis (PrEP) uptake and the importance of sexual health screening. Additionally, Dr Elopre shares her best practices for receiving an adequate sexual health history from her patients.

Presenters:

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, Alabama

Moderator

Jason Farley, PhD, MPH, ANP-BC, FAAN AACRN
Endowed Professor of Nursing Leadership and Innovation
Johns Hopkins University School of Nursing
Director, Center for Infectious Disease and Nursing Innovation
Adult Nurse Practitioner, Infectious Diseases
Johns Hopkins Medicine
Baltimore, Maryland

There’s more to winning field sprints than having incredible peak power numbers. Neal and Jeff break down the skills, power, and speed to be a great sprinter, from understanding the demands of the course, positioning in the pack, how to ride climbs and descents, managing your team’s effort and why five-minute power (MAP) matters so much to get into the best position for victory.

Open The Road  by Wahoo 

https://wahoox.forum.wahoofitness.com/t/new-knowledge-episode-why-winning-sprints-takes-much-more-than-sprinting/19201

The way the pros race up mountains is quite dramatic — and specific to race situations. Neal and Mac explain the tactics of climbing in professional racing while offering their top tips to get you to the top of your local climb faster than ever before.

**Learn more:**

https://www.wahoofitness.com/blog/ask-experts-hill-climbing-101/

**Try the SYSTM Training App free for 14 days.**

https://www.wahoofitness.com/systm/getting-started

Have questions? Please ask us here! 

https://wahoox.forum.wahoofitness.com/t/new-knowledge-episode-climbing-the-difference-between-the-pros-and-you/19080

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from EASL 2022, including:

• Novel HBV therapeutics, including the REEF-2, B-Clear, and SAVE-1 studies
• HBV cure from the Everest Project in China
• HDV therapeutics from MYR301 and a study of bulevirtide in patients with cirrhosis and portal hypertension
• HCV retreatment in patients with prior direct-acting antiviral therapy failure

Presenter: 

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I 
JW Goethe University Hospital 
Frankfurt, Germany

Follow along with the downloadable slideset at:
https://bit.ly/3yJAruD

Link to full program: 
https://bit.ly/3AjCNBC

90 hours at over 40kph. Decreases in bone density.  Dynamic calculations on time cuts. Dramatic maximum heart rate drops. More than 5,000 calories a day. Completing a Grand Tour is tough and our sports science team of Neal Henderson and Mac Cassin dive deep into the details -- interrupted only by a few colorful stories -- to help you understand what it really takes.

**Learn more:**

https://www.wahoofitness.com/blog/numbers-takes-race-grand-tour/

**Try the SYSTM Training App free for 14 days.**

https://www.wahoofitness.com/systm/getting-started

Have questions? Please ask us here! 

https://wahoox.forum.wahoofitness.com/t/new-knowledge-episode-what-it-takes-to-ride-a-grand-tour/19028

Episode 3 of this series features Anna Cristina L. dela Cruz, MD, in conversation with patient Melody Cheng about Melody’s decision to start hepatitis B virus (HBV) antiviral therapy during pregnancy. This podcast also discusses recommended approaches to preventing HBV transmission from mother to child, current recommendations on starting treatment for chronic HBV infection, and the issues around stopping treatment.

Presenter:
Anna Christina L. dela Cruz, MD
Associate Professor
Division of Digestive Diseases and Nutrition
Department of Internal Medicine
University of Kentucky
Lexington, Kentucky

Content based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.

Link to full program: 
https://bit.ly/3KmJvZt

In this episode, Jürgen K. Rockstroh, MD, and Giada Sebastiani, MD, discuss key strategies to appropriately screen for, identify, and manage nonalcoholic steatohepatitis in persons with HIV. They also answer pressing questions from healthcare professionals.

Presenters: 

Jürgen K. Rockstroh, MD
Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany

Giada Sebastiani, MD
Associate Professor of Medicine
McGill University Health Centre
Division of Gastroenterology and Hepatology and Division of Infectious Diseases
Clinician Scientist
Research Institute of McGill University Health Centre
Montreal, Quebec, Canada

Content based on an online CME program supported by an educational grant from Theratechnologies Inc.

Link to full program:
https://bit.ly/363orZ9

In this episode from the series “Key Decisions in HIV Care,” Daria Podlekareva, MD, PhD, and Mark S. Sulkowski, MD, discuss important considerations for ART use in patients with coinfections, including:

• DHHS testing and treatment recommendations for HBV in patients with HIV
• Data suggesting that tenofovir alone may not suppress HBV in all PWH
• Data from NA-ACCORD showing that incomplete HBV DNA suppression is associated with HCC in patients with HIV/HBV
• Data for the use of entecavir as an add-on therapy if an HIV ART regimen is not HBV active
• Data showing that lamivudine alone is associated with resistance in patients with HIV/HBV
• Discussion of HBV management in the setting of 2-drug regimens for HIV if the patient is coinfected
• Recommendations from the DHHS, EACS, and WHO to start ART as soon as possible in patients with TB/HIV coinfection
• Data from the SAPiT, ACTG A5221 STRIDE, and CAMELIA studies to show the benefits of early ART in patients with TB/HIV
• Recommendations from the EACS guidelines on what ART regimens are recommended with TB/HIV
• Drug-drug interaction considerations between ART and TB treatment
• Discussion of the prevention and management of TB-associated IRIS

Presenters:

Daria Podlekareva, MD, PhD
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark  

Mark S. Sulkowski, MD
Professor of Medicine
Medical Director, Viral Hepatitis Center
Chief, Infectious Disease
Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with slides:
https://bit.ly/3zHySMO

See the entire program at:
https://bit.ly/2TXTYWx

In this week's episode, Wahoo Sports Science coach Neal Henderson is joined by Rohan Dennis. For the past nine years Neal has been Rohan's coach, helping him achieve some impressive results, including a World Hour Record, Olympic medals, Grand Tour stage wins, and several World Championship titles. Neal and Rohan talk about their history working together, Rohan's recent move to Jumbo Visma, and what lies ahead for the talented Aussie rider. Coach Neal might even show his softer side as he reflects on their nearly decade-long relationship.

Have a question? Ask and get answers here! 

https://systm.forum.wahoofitness.com/t/new-episode-w-special-guest-world-champ-rohan-dennis/15629